PARIS, FRANCE / ACCESSWIRE / February 13, 2024 / Abivax SA (Euronext Paris:ABVX))(NASDAQ:ABVX) ('Abivax' or the 'Company'), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced that four scientific abstracts on its lead drug candidate, obefazimod for the treatment of moderately to severely active ulcerative colitis (UC), will be presented during the 19th Congress of the European Crohn's and Colitis Organisation (ECCO) on February 21-24, 2024, in Stockholm, Sweden..

法国巴黎/ACCESSWIRE/2024年2月13日/Abivax SA（Euronext PARIS:ABVX））（纳斯达克：ABVX）（“Abivax”或“公司”），这是一家临床阶段的生物技术公司，专注于开发利用人体自然调节机制稳定慢性炎性疾病患者免疫反应的治疗方法，今天宣布，关于其主要候选药物obefazimod治疗中度至重度活动性溃疡性结肠炎（UC）的四篇科学摘要将于2024年2月21日至24日在瑞典斯德哥尔摩举行的欧洲克罗恩病和结肠炎组织（ECCO）第19届大会上发表。。

'We are delighted that all four submitted abstracts have been accepted for presentations at ECCO. We look forward to scientific exchange with the IBD community at ECCO,' said Sheldon Sloan, M.D., M. Bioethics, Chief Medical Officer of Abivax. 'The ECCO Congress provides an excellent platform to present new data and to continue raising awareness of the unique mechanism of action of obefazimod, which available data indicate exerts its anti-inflammatory activity by stabilizing the immune response in patients with ulcerative colitis.'.

“我们很高兴所有四份提交的摘要都被ECCO接受了。Abivax首席医疗官、医学博士、生物伦理学硕士谢尔顿·斯隆（SheldonSloan）说，我们期待着与ECCO的IBD社区进行科学交流ECCO大会提供了一个很好的平台，可以提供新的数据，并继续提高人们对obefazimod独特作用机制的认识，现有数据表明，obefazimod通过稳定溃疡性结肠炎患者的免疫反应来发挥其抗炎活性。”。

Abivax has also sponsored a scientific symposium titled 'Expanding the Armamentarium: Emerging MOAs for Treating Ulcerative Colitis' featuring speakers Prof. Bruce E. Sands, M.D., M.S. (United States), and Prof. Raja Atreya, M.D. (Germany), on February 23, 2024, at 7:15-8:15 a.m. CET in room A12.

Abivax还于2024年2月23日上午7:15-8:15在A12室主办了一场题为“扩大军备：治疗溃疡性结肠炎的新兴MOA”的科学研讨会，演讲嘉宾为美国医学博士Bruce E.Sands教授和德国医学博士Raja Atreya教授。

The Symposium will be broadcasted live and is accessible publicly here. No ECCO registration is required to view the broadcast.

研讨会将进行现场直播，并可在此公开访问。观看广播不需要ECCO注册。

For more information visit the Abivax booth at the ECCO exhibitor hall (booth #15) or see congress details at the ECCO website.

欲了解更多信息，请访问ECCO参展商大厅（展位#15）的Abivax展位，或查看ECCO网站上的大会详情。

Obefazimod data to be presented:

拟提交的Obefazimod数据：

Presentation Title

演示文稿标题

Session

会话

Presenter

演示者

Presentation/ Session Number

演示/会议编号

Session Hall

会议厅

Date and Time (CET)

日期和时间（CET）

Digital Oral Presentations

数字口头演示

Efficacy and safety of obefazimod in UC patients at weeks 48 and 96 of an open-label maintenance study among clinical responders at week 8 of the Phase 2b induction trial

在2b期诱导试验的第8周，临床应答者在开放标签维持研究的第48周和第96周，奥贝法齐莫对UC患者的疗效和安全性

Session 2: Clinical trials 1

第2部分：临床试验1

Prof. Séverine Vermeire, M.D., Ph.D.

Séverine Vermeire教授，医学博士，博士。

Head of the IBD Center at the University Hospitals Leuven, Belgium, and principal investigator in Europe for the study programs conducted and ongoing with obefazimod in UC

比利时鲁汶大学医院炎症性肠病中心主任，欧洲首席研究员，负责与加州大学obefazimod进行和正在进行的研究项目

EC24-1273

酶代码EC24-1273

Digital Oral Presentation (DOP)-12

数字口头演示（DOP）-12

A7

A7级

Feb. 22, 2024

2024年2月22日

Presentation time: 5:57-6:03 p.m.

演讲时间：下午5:57-6:03。

Session time: 5:45-6:45 p.m.

会议时间：下午5:45-6:45。

Efficacy of once-daily, orally administered obefazimod in patients with moderately to severely active UC at weeks 8, 48, and 96 broken down by induction treatment dose

每日一次口服奥贝法齐莫对中度至重度活动性UC患者在第8、48和96周的疗效（按诱导治疗剂量细分）

DOP Session 8: Clinical trials 3

DOP课程8：临床试验3

Prof. Bruce E. Sands, M.D., M.S.

Bruce E.Sands教授，医学博士，硕士。

Dr. Burrill B. Crohn Professor of Medicine and Chief, Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, NY

Burrill B.Crohn博士，医学教授，纽约西奈山伊坎医学院消化内科主任Henry D.Janowitz博士

EC24-1275

酶代码EC24-1275

Digital Oral Presentation (DOP)-71

数字口头演示（DOP）-71

A12

A12级

Feb. 23, 2024

2024年2月23日

Presentation time: 6:22-6:28 p.m.

演讲时间：下午6:22-6:28。

Session time: 5:40-6:40 p.m.

会议时间：下午5:40-6:40。

Poster Presentations

墙报交流

Obefazimod and its active metabolites ABX-464-N-Glu act by stabilizing protein-protein interaction among key RNA biogenesis partners, CBC and ARS2

Obefazimod及其活性代谢产物ABX-464-N-Glu通过稳定关键RNA生物发生伙伴CBC和ARS2之间的蛋白质-蛋白质相互作用起作用

Guided Poster Session

引导海报会议

Didier Scherrer, Ph.D.

Didier Scherrer博士。

Chief Scientific Officer, Abivax

Abivax首席科学官

EC24-1272

酶代码EC24-1272

Poster Presentation-025

海报展示-025

Poster Exhibition Hall A

海报展示厅A

Feb. 23, 2024

2024年2月23日

Session time: 12:40-1:40 p.m.

会议时间：下午12:40-1:40。

Efficacy and safety of de-escalation from 50 mg to 25 mg of oral, once-daily, obefazimod for the third and fifth year of open-label maintenance treatment in patients with moderately to severely active ulcerative colitis (UC): An interim analysis

中度至重度活动性溃疡性结肠炎（UC）患者开放标签维持治疗的第三年和第五年，每日一次口服奥贝法齐莫从50 mg降至25 mg的疗效和安全性：中期分析

Guided Poster Session

引导海报会议

Prof. Parambir S. Dulai, M.D.

医学博士Parambir S.Dulai教授。

Associate Professor of Medicine in the Division of Gastroenterology and Hepatology at Northwestern University, Evanston, Illinois.

伊利诺伊州埃文斯顿西北大学胃肠学和肝病学系医学副教授。

EC24-1277

酶代码EC24-1277

Poster Presentaition-985

海报展示-985

Poster Exhibition Hall A

海报展示厅A

Feb. 23, 2024

2024年2月23日

Session time: 12:40-1:40 p.m.

会议时间：下午12:40-1:40。

About Obefazimod

关于Obefazimod

Obefazimod, Abivax's lead investigational drug candidate, is an oral small molecule that was demonstrated to enhance the expression of a single microRNA, miR-124. Phase 2 clinical trials in patients with UC have generated positive topline data, resulting in the initiation of a pivotal global Phase 3 clinical trial program (ABTECT Program), with first patients enrolled in the United States in October 2022.

Abivax的主要研究药物候选药物Obefazimod是一种口服小分子，已被证明可增强单个microRNA miR-124的表达。UC患者的2期临床试验产生了积极的topline数据，导致启动了关键的全球3期临床试验计划（ABTECT计划），2022年10月首批患者入选美国。

Initiation of a Phase 2b clinical trial in Crohn's disease is expected in Q3 2024, and exploration of potential combination therapy opportunities in UC is ongoing..

预计2024年第三季度将开始克罗恩病2b期临床试验，并正在探索UC潜在的联合治疗机会。。

About Abivax

关于Abivax

Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Based in France and the United States, Abivax's lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis.

Abivax是一家临床阶段的生物技术公司，专注于开发利用人体自然调节机制来稳定慢性炎症性疾病患者免疫反应的疗法。Abivax的主要候选药物obefazimod（ABX464）位于法国和美国，正在进行治疗中度至重度活动性溃疡性结肠炎的3期临床试验。

More information on the Company is available at www.abivax.com. Follow us on LinkedIn and on X, formerly Twitter, @ABIVAX..

有关该公司的更多信息，请访问www.abivax.com。请在LinkedIn和X（以前的推特@abivax）上关注我们。。

Contacts:

联系人：

Abivax Communications

Abivax通信

Regina Jehle

Regina针

regina.jehle@abivax.com

regina.jehle@abivax.com

+33 06 24 60 69 63

+33 06 24 60 69 63

Abivax Investor Relations

Abivax投资者关系

Patrick Malloy

帕特里克·马洛伊

patrick.malloy@abivax.com

patrick.malloy@abivax.com

+1 847 987 4878

+1 847 987 4878

FORWARD-LOOKING STATEMENTS

前瞻性声明

This press release contains forward-looking statements, forecasts and estimates, including those relating to the Company's business and financial objectives. Words such as 'design,' 'expect,' 'forward,' 'future,' 'potential,' 'plan,' 'project' and variations of such words and similar expressions are intended to identify forward-looking statements.

本新闻稿包含前瞻性声明、预测和估计，包括与公司业务和财务目标有关的声明、预测和估计。诸如“设计”、“期望”、“未来”、“未来”、“潜力”、“计划”、“项目”等词语以及这些词语和类似表达的变体旨在识别前瞻性陈述。

Although Abivax's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks, contingencies and uncertainties, many of which are difficult to predict and generally beyond the control of Abivax, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements.

尽管Abivax管理层认为这些前瞻性声明中反映的预期是合理的，但投资者应注意，前瞻性信息和声明会受到各种风险、意外事件和不确定性的影响，其中许多风险、意外事件和不确定性很难预测，通常超出Abivax的控制范围，这可能导致实际结果和发展与前瞻性信息和声明中表达的、暗示的或预测的结果和发展存在重大差异。

A description of these risks, contingencies and uncertainties can be found in the documents filed by the Company with the French Autorité des Marchés Financiers pursuant to its legal obligations including its universal registration document (Document d'Enregistrement Universel). These risks, contingencies and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug candidate, as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates.

这些风险、意外事件和不确定性的描述可以在公司根据其法律义务（包括其通用注册文件（document d'Enregistrement Universel））向法国马歇尔汽车金融公司提交的文件中找到。这些风险、意外事件和不确定性包括研发固有的不确定性、未来的临床数据和分析、监管机构（如FDA或EMA）关于是否以及何时批准任何候选药物的决定，以及他们关于标签和其他可能影响此类候选产品可用性或商业潜力的事项的决定。

Special consideration should be given to the potential hurdles of clinical and pharmaceutical development including further assessment by the company and regulatory agencies and IRBs/ethics committees following the assess.

应特别考虑临床和药物开发的潜在障碍，包括公司和监管机构以及IRB/道德委员会在评估后的进一步评估。

SOURCE: ABIVAX

来源：ABIVAX

View the original press release on accesswire.com

在accesswire.com上查看原始新闻稿